NexPoint Event Driven Fund issued a demand letter to the Board of Directors of Paratek Pharmaceuticals, to make available all books and records surrounding the proposed acquisition of the Company in order to investigate whether any board members breached their fiduciary duties in connection with the proposed acquisition. NexPoint Event Driven Fund is advised by NexPoint Asset Management, and together with other stockholders, are members of a group who beneficially own approximately 11.7% of the Company’s outstanding common stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRTK:
- NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point Capital
- Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
- Paratek Pharmaceuticals announces modification of BARDA contract
- Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter
- Paratek Pharmaceuticals acknowledges receipt of NexPoint letter